Poly-ADP-ribose polymerase (PARP) inhibitors (PARPi) were first identified as potential targeted cancer treatments for tumours with deficiencies in the homologous recombination (HR) pathway of double strand break (DSB) repair [1]. This evidence concerns the gene PARP1 and neoplasm.